Summary by Moomoo AI
Conduit Pharmaceuticals Inc. has issued a $5,737,500 convertible promissory note to A.G.P./Alliance Global Partners, due November 25, 2025. The note accrues 5.5% annual interest and is convertible to common stock at $0.10 per share, subject to adjustments and stockholder approval. Concurrently, Conduit amended its existing $2.65 million note with Nirland Limited, allowing conversion at the same rate.Both notes require stockholder approval for conversion and could potentially result in the issuance of up to 133 million new common shares combined. The company must file a resale registration statement for the new note within specified timeframes. If stockholder approval for the Nirland note conversion is not obtained by January 9, 2025, Conduit faces a $100,000 per day penalty.The notes are unsecured, governed by New York law, and were issued under exemptions from SEC registration requirements. Conduit may suspend the use of the prospectus for up to 60 total trading days in a 12-month period if needed to amend the registration statement.
